Bone marrow GvHD after allogeneic hematopoietic stem cell transplantation

Frontiers in Immunology

Volumn 7, Issue MAR, 2016, Pages

  Szyska, Martin ^a   Na, Il Kang ^a,b  

^a Experimental and Clinical Research Center ECRC   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

AlloHSCT; Bone marrow; Bone marrow stroma; GvHD; GvL; GvT; Memory niche; Minor antigen

Indexed keywords

CD40 ANTIGEN; FAS LIGAND; GAMMA INTERFERON; GRANZYME; INTERLEUKIN 1; INTERLEUKIN 7; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MINOR HISTOCOMPATIBILITY ANTIGEN; PERFORIN; STROMAL CELL DERIVED FACTOR 1; TUMOR NECROSIS FACTOR ALPHA;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOIMMUNITY; ANTIBODY TITER; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; BONE MARROW; BONE MARROW DEPRESSION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CYTOTOXIC T LYMPHOCYTE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTIC INFILTRATION; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; REGULATORY T LYMPHOCYTE; SHORT SURVEY; UPREGULATION;

EID: 84964663615     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2016.00118     Document Type: Short Survey

References (57)

1. Korngold R, Sprent J. Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T cells from marrow. J Exp Med (1978) 148:1687-98. doi: 10.1084/jem.148.6.1687.
2. Porter DL, Roth MS, McGarigle C, Ferrara J, Antin JH. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med (1994) 330:100-6. doi:10.1056/NEJM199401133300204.
3. Bruno B, Gooley T, Sullivan KM, Davis C, Bensinger WI, Storb R, et al. Secondary failure of platelet recovery after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2001) 7:154-62. doi:10.1053/bbmt.2001.v7.pm11302549.
4. Mensen A, Jöhrens K, Anagnostopoulos I, Demski S, Oey M, Stroux A, et al. T-cell infiltration of the human bone marrow during acute GvHD is associated with impaired B-cell reconstitution and function after allogeneic-HSCT. Blood (2014) 124:963-72. doi:10.1182/blood-2013-11-539031.
5. Shono Y, Ueha S, Wang Y, Abe J, Kurachi M, Matsuno Y, et al. Bone marrow graft-versus-host disease: early destruction of hematopoietic niche after MHC-mismatched hematopoietic stem cell transplantation. Blood (2010) 115:5401-11. doi:10.1182/blood-2009-11-253559.
6. Felix NJ, Allen PM. Specificity of T-cell alloreactivity. Nat Rev Immunol (2007) 7:942-53. doi:10.1038/nri2200.
7. Suchin EJ, Langmuir PB, Palmer E, Sayegh MH, Wells AD, Turka LA. Quantifying the frequency of alloreactive T cells in vivo: new answers to an old question. J Immunol (2001) 166:973-81. doi:10.4049/jimmunol.166.2.973.
8. Joffre OP, Segura E, Savina A, Amigorena S. Cross-presentation by dendritic cells. Nat Rev Immunol (2012) 12:557-69. doi:10.1038/nri3254.
9. Anderson BE, McNiff JM, Jain D, Blazar BR, Shlomchik WD, Shlomchik MJ. Distinct roles for donor- and host-derived antigen-presenting cells and costimulatory molecules in murine chronic graft-versus-host disease: requirements depend on target organ. Blood (2005) 105:2227-34. doi:10.1182/blood-2004-08-3032.
10. Van Bergen CA, Rutten CE, Van Der Meijden ED, Van Luxemburg-Heijs SA, Lurvink EG, Houwing-Duistermaat JJ, et al. High-throughput characterization of 10 new minor histocompatibility antigens by whole genome association scanning. Cancer Res (2010) 70:9073-83. doi:10.1158/0008-5472.CAN-10-1832.
11. DeLuca DS, Eiz-Vesper B, Ladas N, Khattab BA-M, Blasczyk R. High-throughput minor histocompatibility antigen prediction. Bioinformatics (2009) 25:2411-7. doi:10.1093/bioinformatics/btp404.
12. Shustov A, Nguyen P, Finkelman F, Elkon KB, Via CS. Differential expression of Fas and Fas ligand in acute and chronic graft-versus-host disease: up-regulation of Fas and Fas ligand requires CD8+ T cell activation and IFN-γ production. J Immunol (1998) 161:2848-55.
13. Van den Brink MRM, Burakoff SJ. Cytolytic pathways in haematopoietic stem-cell transplantation. Nat Rev Immunol (2002) 2:273-81. doi:10.1038/nri775.
14. Baker MB, Riley RL, Podack ER, Levy RB. Graft-versus-host-disease-associated lymphoid hypoplasia and B cell dysfunction is dependent upon donor T cell-mediated Fas-ligand function, but not perforin function. Proc Natl Acad Sci U S A (1997) 94:1366-71. doi:10.1073/pnas.94.4.1366.
15. Schmaltz C, Alpdogan O, Horndasch KJ, Muriglan SJ, Kappel BJ, Teshima T, et al. Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect. Blood (2001) 97:2886-95. doi:10.1182/blood.V97.9.2886.
16. Lin L, Couturier J, Yu X, Medina MA, Kozinetz CA, Lewis DE. Granzyme B secretion by human memory CD4 T cells is less strictly regulated compared to memory CD8 T cells. BMC Immunol (2014) 15:36. doi:10.1186/s12865-014-0036-1.
17. Marks L, Altman NH, Podack ER, Levy RB. Donor T cells lacking Fas ligand and perforin retain the capacity to induce severe GvHD in minor histocompatibility antigen mismatched bone-marrow transplantation recipients. Transplantation (2004) 77:804-12. doi:10.1097/01.TP.0000110416.96307.D5.
18. Kaplan MJ, Ray D, Mo R-R, Yung RL, Richardson BC. TRAIL (Apo2 ligand) and TWEAK (Apo3 ligand) mediate CD4+ T cell killing of antigen-presenting macrophages. J Immunol (2000) 164:2897-904. doi:10.4049/jimmunol.164.6.2897.
19. Parkman R. Clonal analysis of murine graft-vs-host disease. I. Phenotypic and functional analysis of T lymphocyte clones. J Immunol (1986) 136:3543-8.
20. Tyndall A, Dazzi F. Chronic GVHD as an autoimmune disease. Best Pract Res Clin Haematol (2008) 21:281-9. doi:10.1016/j.beha.2008.03.003.
21. Pulanic D, Lozier JN, Pavletic SZ. Thrombocytopenia and hemostatic disorders in chronic graft versus host disease. Bone Marrow Transplant (2009) 44:393-403. doi:10.1038/bmt.2009.196.
22. Goker H, Haznedaroglu IC, Chao NJ. Acute graft-vs-host disease: pathobiology and management. Exp Hematol (2001) 29:259-77. doi:10.1016/S0301-472X(00)00677-9.
23. Gratwohl A, Brand R, Frassoni F, Rocha V, Niederwieser D, Reusser P, et al. Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time. Bone Marrow Transplant (2005) 36:757-69. doi:10.1038/sj.bmt.1705140.
24. Holländer GA, Widmer B, Burakoff SJ. Loss of normal thymic repertoire selection and persistence of autoreactive T cells in graft vs host disease. J Immunol (1994) 152:1609-17.
25. Swain SL, McKinstry KK, Strutt TM. Expanding roles for CD4+ T cells in immunity to viruses. Nat Rev Immunol (2012) 12:136-48. doi:10.1038/nri3152.
26. Klein L, Hinterberger M, Wirnsberger G, Kyewski B. Antigen presentation in the thymus for positive selection and central tolerance induction. Nat Rev Immunol (2009) 9:833-44. doi:10.1038/nri2669.
27. Müller AMS, Linderman JA, Florek M, Miklos D, Shizuru JA. Allogeneic T cells impair engraftment and hematopoiesis after stem cell transplantation. Proc Natl Acad Sci U S A (2010) 107:14721-6. doi:10.1073/pnas.1009220107.
28. Yao Y, Song X, Cheng H, Tang G, Hu X, Zhou H, et al. Dysfunction of bone marrow vascular niche in acute graft-versus-host disease after MHC-haploidentical bone marrow transplantation. PLoS One (2014) 9:e104607. doi:10.1371/journal.pone.0104607.
29. Storek J, Wells D, Dawson MA, Storer B, Maloney DG. Factors influencing B lymphopoiesis after allogeneic hematopoietic cell transplantation. Blood (2001) 98:489-91. doi:10.1182/blood.V98.2.489.
30. Manz RA, Thiel A, Radbruch A. Lifetime of plasma cells in the bone marrow. Nature (1997) 388:133-4. doi:10.1038/40540.
31. Tokoyoda K, Zehentmeier S, Hegazy AN, Albrecht I, Grün JR, Löhning M, et al. Professional memory CD4+ T lymphocytes preferentially reside and rest in the bone marrow. Immunity (2009) 30:721-30. doi:10.1016/j.immuni.2009.03.015.
32. Di Rosa F, Pabst R. The bone marrow: a nest for migratory memory T cells. Trends Immunol (2005) 26:360-6. doi:10.1016/j.it.2005.04.011.
33. Becker TC, Coley SM, Wherry EJ, Ahmed R. Bone marrow is a preferred site for homeostatic proliferation of memory CD8 T cells. J Immunol (2005) 174:1269-73. doi:10.4049/jimmunol.174.3.1269.
34. Mazo IB, Honczarenko M, Leung H, Cavanagh LL, Bonasio R, Weninger W, et al. Bone marrow is a major reservoir and site of recruitment for central memory CD8+ T cells. Immunity (2005) 22:259-70. doi:10.1016/j.immuni.2005.01.008.
35. Zhang J, Niu C, Ye L, Huang H, He X, Tong WG, et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature (2003) 425:836-41. doi:10.1038/nature02041.
36. Méndez-Ferrer S, Michurina TV, Ferraro F, Mazloom AR, Macarthur BD, Lira SA, et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature (2010) 466:829-34. doi:10.1038/nature09262.
37. Kiel MJ, Yilmaz OH, Iwashita T, Yilmaz OH, Terhorst C, Morrison SJ. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell (2005) 121:1109-21. doi:10.1016/j.cell.2005.05.026.
38. Sugiyama T, Kohara H, Noda M, Nagasawa T. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity (2006) 25:977-88. doi:10.1016/j.immuni.2006.10.016.
39. Kiel MJ, Morrison SJ. Uncertainty in the niches that maintain haematopoietic stem cells. Nat Rev Immunol (2008) 8:290-301. doi:10.1038/nri2279.
40. Nagasawa T. Microenvironmental niches in the bone marrow required for B-cell development. Nat Rev Immunol (2006) 6:107-16. doi:10.1038/nri1780.
41. Li HH, Wang YW, Chen R, Zhou B, Ashwell JD, Fornace AJ Jr. Ionizing radiation impairs T cell activation by affecting metabolic reprogramming. Int J Biol Sci (2015) 11:726-36. doi:10.7150/ijbs.12009.
42. Sugrue T, Lowndes NF, Ceredig R. Mesenchymal stromal cells: radio-resistant members of the bone marrow. Immunol Cell Biol (2013) 91:5-11. doi:10.1038/icb.2012.61.
43. Shlomchik WD, Couzens MS, Tang CB, McNiff J, Robert ME, Liu J, et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science (1999) 285:412-5. doi:10.1126/science.285.5426.412.
44. Pober JS, Sessa WC. Evolving functions of endothelial cells in inflammation. Nat Rev Immunol (2007) 7:803-15. doi:10.1038/nri2171.
45. Li JH, Pober JS. The cathepsin B death pathway contributes to TNF plus IFN-γ-mediated human endothelial injury. J Immunol (2005) 175:1858-66. doi:10.4049/jimmunol.175.3.1858.
46. Tsuboi M, Kawakami A, Nakashima T, Matsuoka N, Urayama S, Kawabe Y, et al. Tumor necrosis factor-a and interleukin-1β increase the Fas-mediated apoptosis of human osteoblasts. J Lab Clin Med (1999) 134:222-31. doi:10.1016/S0022-2143(99)90201-9.
47. Schrum LW, Bost KL, Hudson MC, Marriott I. Bacterial infection induces expression of functional MHC class II molecules in murine and human osteoblasts. Bone (2003) 33:812-21. doi:10.1016/S8756-3282(03)00265-5.
48. Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation (2003) 75:389-97. doi:10.1097/01.TP.0000045055.63901.A9.
49. Fasslrinner F, Wobus M, Duryagina R, Müller K, Stopp S, Wehner R, et al. Differential effects of mixed lymphocyte reaction supernatant on human mesenchymal stromal cells. Exp Hematol (2012) 40:934-44. doi:10.1016/j.exphem.2012.07.011.
50. Ryan JM, Barry FP, Murphy JM, Mahon BP. Mesenchymal stem cells avoid allogeneic rejection. J Inflamm Lond Engl (2005) 2:8. doi:10.1186/1476-9255-2-8.
51. Okamoto T, Kanamaru A, Kakishita E, Nagai K. Stromal fibroblastic and hematopoietic progenitors in patients with graft-versus-host disease (GVHD). Int J Hematol (1991) 54:299-306.
52. de Bruin AM, Demirel ö, Hooibrink B, Brandts CH, Nolte MA. Interferon-γ impairs proliferation of hematopoietic stem cells in mice. Blood (2013) 121:3578-85. doi:10.1182/blood-2012-05-432906.
53. Awaya N, Rupert K, Bryant E, Torok-Storb B. Failure of adult marrow-derived stem cells to generate marrow stroma after successful hematopoietic stem cell transplantation. Exp Hematol (2002) 30:937-42. doi:10.1016/S0301-472X(02)00821-4.
54. Fujisaki J, Wu J, Carlson AL, Silberstein L, Putheti P, Larocca R, et al. In vivo imaging of Treg cells providing immune privilege to the haematopoietic stem-cell niche. Nature (2011) 474:216-9. doi:10.1038/nature10160.
55. Sercan Alp ö, Durlanik S, Schulz D, McGrath M, Grün JR, Bardua M, et al. Memory CD8+ T cells colocalize with IL-7+ stromal cells in bone marrow and rest in terms of proliferation and transcription. Eur J Immunol (2015) 45:975-87. doi:10.1002/eji.201445295.
56. Cutler C, Miklos D, Kim HT, Treister N, Woo SB, Bienfang D, et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood (2006) 108:756-62. doi:10.1182/blood-2006-01-0233.
57. Ringdén O, Uzunel M, Rasmusson I, Remberger M, Sundberg B, Lönnies H, et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation (2006) 81:1390-7. doi:10.1097/01.tp.0000214462.63943.14.